The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Debt | Alive

Total Raised


Last Raised

$1M | 1 yr ago

About Viscient Biosciences

Viscient Biosciences is a developer of drugs for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis.

Viscient Biosciences Headquarter Location

3550 General Atomics Court

San Diego, California, 92121,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Viscient Biosciences Patents

Viscient Biosciences has filed 2 patents.

The 3 most popular patent topics include:

  • Diseases of liver
  • Genetics
  • Hepatitis
patents chart

Application Date

Grant Date


Related Topics



Hepatology, Diseases of liver, Inflammations, Hepatitis, Genetics


Application Date


Grant Date


Related Topics

Hepatology, Diseases of liver, Inflammations, Hepatitis, Genetics



Latest Viscient Biosciences News

Organovo’s Keith Murphy Again as Govt Chairman

Sep 24, 2020

The best 3d print 2020 Founder and former CEO of Organovo, Keith Murphy, is again as the corporate’s newly appointed Govt Chairman of the Board. The information comes three years after Murphy left the pioneering biotechnology enterprise to begin one other enterprise, a seven-person biotech 3D tissue know-how and multi-omics startup referred to as Viscient Biosciences. Throughout this time, Organovo struggled to seek out the sources wanted to advance its highly-anticipated 3D printed developments of residing human liver tissue for organ transplant. Since 2007, San-Diego based mostly Organovo had been one of many huge driving forces behind bioprinting know-how. Nonetheless, firm officers halted all analysis and improvement lead packages in August 2019 and laid off 69 p.c of its general workforce – roughly 40 positions – to increase its money runway because it explored accessible “strategic alternate options to generate worth from its know-how platform and mental property.” Consequently, the corporate recorded a restructuring cost of near $1.three million, and shortly thereafter, in November, it bought Samsara Sciences, its human major liver and kidney cell isolation enterprise, to Virginia-based LifeNet Well being for $1.5 million. Regardless that the corporate had anticipated in 2018 that Organovo would have two liver therapeutic tissue packages on monitor for an Investigational New Drug (IND) focused for 2020 beneath the steering of its Chief Medical Officer, Steven G. Hughes, issues did not go as deliberate. Clearly, as we transfer by means of the fiscal 12 months 2020, there was no information in any respect of any advances in Organovo merchandise. NovoGen Bioprinter Platform. (Picture courtesy of Organovo) Financially, the corporate took a flip for the more serious, in mid-2019, Nasdaq notified Organovo that it not met the necessities to keep up a minimal closing bid worth of $1 per share, as a part of Nasdaq ruling. This meant its inventory must commerce at $1 or increased for at least 10 consecutive days inside a six month interval to keep away from being delisted from the Nasdaq International Market inventory alternate. General, the corporate inventory worth has been depressed for the previous 5 years, going from USD 5.04 on June 6, 2015, to USD zero.27 on March 25, 2020. Ever since Organovo’s actions and future prospects took a downturn, Murphy took drastic measures with the intention to converse on to stakeholders, attempting to keep away from a potential reverse merger with Tarveda Therapeutics – a privately held most cancers drug developer –, in what he described throughout an interview with, as a “weak monetary place with unexciting know-how and unattractive prospects.” Additionally recognizing that Organovo “is in the present day in its personal precarious place on account of latest mismanagement,” and he concluded that he firmly believes that “the transaction being irrationally championed by the Board runs utterly counter to stockholders’ greatest pursuits.” Murphy, who in the previous couple of years has been closely engaged with Viscient, an organization that makes use of Organovo’s 3D bioprinting know-how in direction of the invention and improvement work in severe types of fatty liver illness referred to as non-alcoholic fatty liver illness (NAFLD) and non-alcoholic steatohepatitis (NASH), had additionally outlined a suggestion to mix his new enterprise with Organovo. However the supply bounced as executives on the time selected to go along with Tarveda. Ultimately, the deliberate merger between Organovo and Tarveda fell by means of and in April 2020 the corporate needed to formally announce that it had terminated the merger settlement. Bioprinted liver by Viscient Biosciences. (Picture courtesy of Viscient Biosciences) Virtually a 12 months after information first got here out of a possible merger between Organovo and Tarveda, in what appeared just like the final try to avoid wasting the sinking enterprise, Murphy discovered his approach again. This time in all probability to maintain the corporate afloat for good as he makes an attempt to advance product improvement and companies of bioprinted human tissues that emulate human biology and illness, enhancing the unique pioneering know-how that helped him discovered the corporate again in 2007. Following the digital 2020 annual assembly on September 15, 2020, and in response to Organovo’s newest cooperation settlement, new appointments to the Board of Administrators additionally embody, Adam Stern, the present CEO of SternAegis Ventures; Alison Milhous, an unbiased guide primarily for all times sciences and know-how firms; David Gobel, CEO of the Methuselah Fund, and Douglas Jay Cohen, CEO of medical machine firm IR Medtek. Moreover, Organovo could have a brand new management group, Viscient co-founder Jeffrey N. Miner would be the new Chief Scientific Officer (CSO); Chris Heberlig has taken on the position as President and Chief Monetary Officer (CFO), and Thomas Jurgensen is the brand new Basic Counsel for Organovo. Whereas the present government officers, together with CEO Taylor Crouch, will step down. Making an attempt to proceed the place Organovo’s earlier leaders left off, means attempting to realize the regulatory approvals for its therapeutic candidates. When Murphy left the corporate in 2017, Organovo had been creating in vivo liver tissues to deal with end-stage liver illness and a choose group of life-threatening, orphan ailments, for which there are restricted remedy choices apart from organ transplantation. Maybe now, we are going to begin to hear excellent news concerning the firm, taking strides to slowly recuperate its main place within the thriving area of biotechnology. With mixed a long time of management expertise within the life science trade, the renewed group might promote innovation to develop regenerative drugs therapies geared toward treating a variety of great liver ailments, which was a part of Organovo’s authentic imaginative and prescient. Please allow JavaScript to view the feedback powered by Disqus. Please give a like or touch upon  Fb for help Us

Viscient Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Viscient Biosciences Rank

  • When was Viscient Biosciences founded?

    Viscient Biosciences was founded in 2017.

  • Where is Viscient Biosciences's headquarters?

    Viscient Biosciences's headquarters is located at 3550 General Atomics Court, San Diego.

  • What is Viscient Biosciences's latest funding round?

    Viscient Biosciences's latest funding round is Debt.

  • How much did Viscient Biosciences raise?

    Viscient Biosciences raised a total of $1M.

  • Who are the investors of Viscient Biosciences?

    Investors of Viscient Biosciences include Thynk Capital.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.